122 related articles for article (PubMed ID: 10414920)
1. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia.
Clark RE; Grzybowski J; Broughton CM; Pender NT; Spiller DG; Brammer CG; Giles RV; Tidd DM
Bone Marrow Transplant; 1999 Jun; 23(12):1303-8. PubMed ID: 10414920
[TBL] [Abstract][Full Text] [Related]
2. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients.
Broughton CM; Spiller DG; Pender N; Komorovskaya M; Grzybowski J; Giles RV; Tidd DM; Clark RE
Leukemia; 1997 Sep; 11(9):1435-41. PubMed ID: 9305594
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
5. Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.
Broughton CM; Sherrington P; Pender NT; Clark RE
Genes Chromosomes Cancer; 1997 Apr; 18(4):292-8. PubMed ID: 9087569
[TBL] [Abstract][Full Text] [Related]
6. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
7. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.
Spiller DG; Giles RV; Grzybowski J; Tidd DM; Clark RE
Blood; 1998 Jun; 91(12):4738-46. PubMed ID: 9616172
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of hematopoietic progenitors in patients with chronic myeloid leukemia.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; Niewint AW; Ossenkoppele GJ
Bone Marrow Transplant; 1997 Nov; 20(10):835-42. PubMed ID: 9404923
[TBL] [Abstract][Full Text] [Related]
9. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Maki G; Tam YK; Berkahn L; Klingemann HG
Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
12. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
[TBL] [Abstract][Full Text] [Related]
14. Collection and analysis of peripheral blood mononuclear cells during haemopoietic recovery following PBSCT for CML: autografting as an in vivo purging manoeuvre?
Spencer A; Granter N; Fagan K; Zaunders G; Deveridge S
Bone Marrow Transplant; 1998 Jan; 21(1):101-3. PubMed ID: 9486504
[TBL] [Abstract][Full Text] [Related]
15. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
Clark RE
Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209
[TBL] [Abstract][Full Text] [Related]
16. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
Prejzner W
Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
[TBL] [Abstract][Full Text] [Related]
17. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.
Rapoport AP; Levine BL; Badros A; Meisenberg B; Ruehle K; Nandi A; Rollins S; Natt S; Ratterree B; Westphal S; Mann D; June CH
Bone Marrow Transplant; 2004 Jan; 33(1):53-60. PubMed ID: 14578928
[TBL] [Abstract][Full Text] [Related]
18. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation.
de Fabritis P; Amadori S; Petti MC; Mancini M; Montefusco E; Picardi A; Geiser T; Campbell K; Calabretta B; Mandelli F
Leukemia; 1995 Apr; 9(4):662-4. PubMed ID: 7536864
[TBL] [Abstract][Full Text] [Related]
19. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
Warashina M; Kuwabara T; Nakamatsu Y; Taira K
Chem Biol; 1999 Apr; 6(4):237-50. PubMed ID: 10099134
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
